DD01
Phase 2A GLP-1/glucagon dual agonist; in the 48-week US Phase 2 liver biopsy analysis, MASH resolution without worsening fibrosis was 62.5% on DD01 versus 5.3% on placebo.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals Reported 48-week US Phase 2 results for its MASH candidate DD01 and has licensed its oral peptide platform abroad. Also seen: Discovery · preclinical
Roles often seen at this stageClinical & PV · Research & development · BD & licensing
A developer of peptide drugs for metabolic disease and fatty-liver disease that owns the ORALINK oral peptide platform.
A GLP-1/glucagon dual agonist; in the 48-week US Phase 2 liver biopsy analysis, MASH resolution without worsening fibrosis was 62.5% on DD01 versus 5.3% on placebo.
A long-acting oral peptide platform; first licensed to Metsera in April 2023 (about KRW 550 billion) with the scope expanded in March 2024.
Completed 48-week dosing of all enrolled patients in the US Phase 2 trial of DD01.
Presented 48-week liver biopsy results of the DD01 Phase 2 trial at EASL Congress 2026.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.